John R. Pinion II
2018
In 2018, John R. Pinion II earned a total compensation of $1.6M as Chief Quality Officer and Executive Vice President, Translational Sciences at Ultragenyx Pharmaceutical, a 17% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $188,030 |
|---|---|
| Option Awards | $728,443 |
| Salary | $430,320 |
| Stock Awards | $217,935 |
| Other | $36,346 |
| Total | $1,601,074 |
Pinion received $728.4K in option awards, accounting for 45% of the total pay in 2018.
Pinion also received $188K in non-equity incentive plan, $430.3K in salary, $217.9K in stock awards and $36.3K in other compensation.
Rankings
In 2018, John R. Pinion II's compensation ranked 6,855th out of 14,244 executives tracked by ExecPay. In other words, Pinion earned more than 51.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,855 out of 14,244 | 52nd |
Division Manufacturing | 2,625 out of 5,759 | 54th |
Major group Chemicals And Allied Products | 989 out of 2,122 | 53rd |
Industry group Drugs | 831 out of 1,811 | 54th |
Industry Pharmaceutical Preparations | 649 out of 1,385 | 53rd |
Source: SEC filing on April 29, 2020.
Pinion's colleagues
We found six more compensation records of executives who worked with John R. Pinion II at Ultragenyx Pharmaceutical in 2018.
2018
Wladimir Hogenhuis
Ultragenyx Pharmaceutical
Chief Operating Officer
2018
Camille Bedrosian
Ultragenyx Pharmaceutical
Chief Medical Officer
2018
Emil Kakkis
Ultragenyx Pharmaceutical
Chief Executive Officer
2018
Shalini Sharp
Ultragenyx Pharmaceutical
Chief Financial Officer
2018
Karah Parschauer
Ultragenyx Pharmaceutical
General Counsel
2018
Thomas Kassberg
Ultragenyx Pharmaceutical